Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance

Clin Microbiol Infect. 2014 Mar;20(3):O188-96. doi: 10.1111/1469-0691.12362. Epub 2013 Sep 18.

Abstract

The role of antibiotic exposure in the evolution and emergence of resistance is challenging to assess. We used carbapenem-resistant Pseudomonas aeruginosa (PA) phenotypes to assess possible factors that are associated with the occurrence and prognosis of such a phenotype and to examine the possible contribution of antibiotic exposure to the evolution of antimicrobial resistance. We conducted a nested case-control study. Cases were defined as patients from whom carbapenem-resistant ureidopenicillin-sensitive PA (CRUS-PA) was isolated; matched controls were PA patients who did not have isolation of CRUS-PA. We analysed potential predictors of CRUS-PA isolation and assessed their clinical significance (mortality and eventual isolation of pan-resistant PA), taking into account antibiotic exposures. We matched 800 case-control pairs. Case patients were more likely to have been exposed to anti-PA carbapenems (OR = 6.9; 95% CI, 2.5-18.6). This finding did not apply to the administration of other antibiotics. The mortality among CRUS-PA patients was similar to that of the controls (HR, 0.8 95%; CI, 0.6-1.1). Subsequent isolation of pan-resistant PA was more frequent among case patients compared with non-pan-resistant controls (p-value <0.05). Among cases, the risk of eventual pan-resistant PA isolation was increased in ertapenem recipients, only after and not prior to the index specimen date (HR, 1.9, 95%; CI, 1.01-3.4). Therefore we suggest that the CRUS-PA phenotype may represent pan beta-lactam resistance and that antibiotic exposure is associated with evolution of PA resistance phenotypes. We demonstrate a novel association of ertapenem with sequentially appearing PA resistance patterns.

Keywords: Carbapenem antibiotics; Pseudomonas aeruginosa; Resistance.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Case-Control Studies
  • Drug Resistance, Bacterial*
  • Ertapenem
  • Humans
  • Microbial Sensitivity Tests
  • Middle Aged
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / drug effects*
  • beta-Lactam Resistance
  • beta-Lactams / pharmacology*
  • beta-Lactams / therapeutic use

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Ertapenem